AbbVie Inc. $ABBV Shares Sold by Curated Wealth Partners LLC

Key Points

• Curated Wealth Partners LLC cut its AbbVie stake by 98.6% in the third quarter, selling 358,772 shares and retaining 5,130 shares worth approximately $1.34 million. Institutional investors and hedge funds collectively own 70.23% of the stock.
• AbbVie reported quarterly EPS of $3.65, topping estimates by $0.04, while revenue rose 10.2% year over year to $16.99 billion. The company declared a quarterly dividend of $1.73 per share, equivalent to a 2.4% annualized yield.
• Analyst sentiment remains favorable, with a consensus rating of “Moderate Buy” and a $277.18 price target, although shares opened at $283.07 and trade at a relatively high P/E ratio of 79.96.

Curated Wealth Partners LLC reduced its position in AbbVie Inc. (NYSE:ABBV - Free Report) by 98.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,130 shares of the company's stock after selling 358,772 shares during the quarter. Curated Wealth Partners LLC's holdings in AbbVie were worth $1,342,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in the business. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors grew its holdings in shares of AbbVie by 4.0% during the third quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors now owns 21,084 shares of the company's stock valued at $5,516,000 after buying an additional 803 shares during the last quarter. Kellett Wealth Advisors LLC increased its position in shares of AbbVie by 1.8% in the 3rd quarter. Kellett Wealth Advisors LLC now owns 3,485 shares of the company's stock valued at $912,000 after acquiring an additional 61 shares during the period. Colorado Capital Management Inc. purchased a new position in AbbVie in the 3rd quarter worth $206,000. KG Capital Management purchased a new position in AbbVie in the 3rd quarter worth $258,000. Finally, Fort Washington Investment Advisors Inc. OH raised its stake in AbbVie by 1.1% in the 3rd quarter. Fort Washington Investment Advisors Inc. OH now owns 210,990 shares of the company's stock worth $55,193,000 after acquiring an additional 2,274 shares during the last quarter. 70.23% of the stock is owned by institutional investors and hedge funds.

AbbVie Price Performance

NYSE ABBV opened at $283.07 on Friday. The company has a market capitalization of $500.13 billion, a PE ratio of 79.96, a P/E/G ratio of 1.29 and a beta of 0.24. The company has a fifty day moving average of $261.95 and a 200 day moving average of $238.90. AbbVie Inc. has a 1 year low of $190.75 and a 1 year high of $291.40.

AbbVie (NYSE:ABBV - Get Free Report) last announced its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, topping the consensus estimate of $3.61 by $0.04. The company had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. The firm's revenue for the quarter was up 10.2% compared to the same quarter last year. During the same period last year, the firm earned $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Research analysts expect that AbbVie Inc. will post 13.94 earnings per share for the current year.

AbbVie Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 2.4%. The ex-dividend date of this dividend is Thursday, October 15th. AbbVie's dividend payout ratio (DPR) is 195.48%.

Insider Buying and Selling

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the firm's stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the sale, the executive vice president directly owned 74,430 shares of the company's stock, valued at $18,607,500. This trade represents a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.06% of the stock is currently owned by company insiders.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: New Phase 3 data for a subcutaneous version of SKYRIZI showed meaningful clinical and endoscopic benefits in adults with moderately to severely active Crohn’s disease. The results could support regulatory review of a more convenient induction option and strengthen confidence that SKYRIZI can help offset the loss of Humira revenue. Abbvie's Crohn's Disease Drug Skyrizi Shows More Positive Results
• Positive Sentiment: Analyst sentiment remains constructive. Royal Bank of Canada reaffirmed an Outperform rating, while Erste Group raised its 2027 EPS estimate to $16.34 from $16.19 and maintained a Buy rating. These views reinforce the argument that AbbVie’s newer drugs are driving sustainable post-Humira growth. Royal Bank Of Canada Reaffirms Outperform Rating for AbbVie
• Positive Sentiment: Investors are also watching early clinical work on oral candidate ABBV-1042. The study remains at an early stage and is being conducted in healthy participants, but positive progress could add value to AbbVie’s long-term pipeline. AbbVie's ABBV-1042 Trial Update
• Neutral Sentiment: AbbVie’s third-quarter earnings report is scheduled for October 30. Investors will be looking for confirmation that SKYRIZI and RINVOQ growth is more than compensating for Humira’s decline; the company’s current guidance calls for third-quarter EPS of $3.84 to $3.88. AbbVie's Q3 2026 Earnings: What to Expect
• Neutral Sentiment: Heavy call-option activity and a broad healthcare-sector rally indicate increased investor interest, but options positioning is not a fundamental catalyst by itself. Lower Treasury yields may also be supporting defensive healthcare shares.
• Negative Sentiment: Some investors remain concerned that AbbVie’s valuation is demanding after its rally. Comparisons with Sanofi have highlighted Sanofi’s stronger outlook and valuation, potentially limiting further upside. Which Pharma Stock Looks More Attractive: Sanofi or AbbVie?

Wall Street Analysts Forecast Growth

ABBV has been the subject of several research analyst reports. Morgan Stanley raised their price objective on AbbVie from $296.00 to $310.00 and gave the stock an "overweight" rating in a research note on Wednesday, October 7th. JPMorgan Chase & Co. upped their target price on AbbVie from $285.00 to $300.00 and gave the company an "overweight" rating in a research report on Thursday, October 8th. Wall Street Zen lowered AbbVie from a "strong-buy" rating to a "buy" rating in a research report on Sunday, July 5th. Cantor Fitzgerald increased their price target on shares of AbbVie from $285.00 to $290.00 and gave the stock an "overweight" rating in a report on Thursday, October 8th. Finally, Piper Sandler raised their price target on shares of AbbVie from $298.00 to $303.00 and gave the stock an "overweight" rating in a research report on Thursday, August 20th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have issued a Hold rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $277.18.

AbbVie Company Profile

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women's health.

The company's products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.